| Literature DB >> 29110732 |
Chae-Seon Hong1, Sang Gyu Ju2, Yong Chan Ahn3,4, Gyu Sang Yoo1, Jae Myoung Noh1, Dongryul Oh1, Kwangzoo Chung1, Hongryull Pyo1, Kwanghyun Jo1.
Abstract
PURPOSE: Radiation pneumonitis (RP) has been a challenging obstacle in treating stage III lung cancer patients. Beam angle optimization (BAO) technique for Tomotherapy was developed to reduce the normal lung dose for stage III non-small cell lung cancer (NSCLC). Comparative analyses on plan quality by 3 different Intensity-modulated radiation therapy (IMRT) methods with BAO were done.Entities:
Keywords: Intensity-modulated radiotherapy; Lung cancer; Radiation pneumonitis; Tomotherapy
Mesh:
Year: 2017 PMID: 29110732 PMCID: PMC5674800 DOI: 10.1186/s13014-017-0905-x
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Patients’ characteristics
| Gender | Age | Primary tumor | Low neck involvement | Clinical stage | Histology | |
|---|---|---|---|---|---|---|
| 1 | Female | 72 years | LUL | Ipsilateral | T1 N3 | Adenocarcinoma |
| 2 | Female | 52 years | RLL | Ipsilateral | T1 N3 | Adenocarcinoma |
| 3 | Male | 58 years | RLL | Ipsilateral | T2 N3 | Squamous |
| 4 | Male | 49 years | RUL/RLL | Ipsilateral | T4 N3 | Adenocarcinoma |
| 5 | Male | 65 years | RUL | Ipsilateral | T3 N3 | Adenocarcinoma |
| 6 | Male | 44 years | LLL | Ipsilateral | T1 N3 | Adenocarcinoma |
| 7 | Male | 67 years | LLL | Contralateral | T2 N3 | Squamous |
| 8 | Male | 58 years | LLL | Contralateral | T2 N3 | Squamous |
| 9 | Male | 64 years | RUL | Bilateral | T2 N3 | Adenocarcinoma |
| 10 | Male | 49 years | RLL | Bilateral | T2 N3 | Adenocarcinoma |
RUL right upper lobe, RLL right lower lobe, LUL left upper lobe, LLL left lower lobe
Fig. 1In order to lower dose to lung, complete and directional blocks were delineated within lung (a). These were located as from PTV as possible, and complete blocks did not allow any beams to pass through them, while directional blocks allowed beams only if they entered PTV first. In order to generate the principles of delineating the complete and directional block, authors collected and analyzed the data of beam arrangements (red dots) in L-IMRT that were actually applied to 59 N3-IIIB NSCLC patients at our institute (b). Dotted arrows represented the most used beam angles for L-IMRT
Dose constraints for inverse planning
| Priority | Structure | Constraints |
|---|---|---|
| 1 | PTV | D95 ≥ 66 Gy (100%) |
| D99 ≥ 61.38 Gy (93%) | ||
| V72.6 (110%) ≤ 1 cm3 | ||
| 1 | P-corda | Dmax ≤ 45 Gy |
| 2 | Normal lung (both lung - PTV) | Dmean ≤ 20 Gy |
| V5 ≤ 65% | ||
| V10 ≤ 45% | ||
| V20 ≤ 35% | ||
| 3 | Heart | V40 < 100% |
| V45 < 66% | ||
| V60 < 33% | ||
| 4 | Esophagus | Dmean ≤ 34 Gy |
D D dose delivered to V% of organ volume, V absolute or percentage of organ volume receiving D Gy or higher, D maximum dose, D mean dose, OARs organ at risks
aP-cord means the planning volume for the spinal cord which was generated by adding 3~5 mm margin to the actual spinal cord
Comparisons of dosimetric parameters and beam delivery time
| Parameters | L-IMRT | TH-IMRT | TD-IMRT |
| |||
|---|---|---|---|---|---|---|---|
| L-IMRT vs. TH-IMRT | L-IMRT vs. TD-IMRT | TH-IMRT vs TD-IMRT | |||||
| Median (IQR) | Median (IQR) | Median (IQR) | |||||
| PTV | CI | 0.75 (0.72, 0.81) | 0.82 (0.79, 0.85) | 0.81 (0.77, 0.83) | 0.006 | 0.006 | 0.580 |
| HI | 1.08 (1.07, 1.08) | 1.06 (1.05, 1.06) | 1.07 (1.05, 1.07) | 0.006 | 0.006 | 0.317 | |
| P-cord | NTCP | 0.82% (0.71, 0.92) | 0.34% (0.23, 0.48) | 0.43% (0.28, 0.55) | 0.006 | 0.006 | 0.393 |
| Dmax | 46.44 Gy (45.56, 47.21) | 44.93 Gy (40.35, 45.33) | 45.55 Gy (41.41, 46.68) | 0.029 | 0.317 | 0.194 | |
| Normal Lung | NTCP | 8.11% (4.90, 10.11) | 6.42% (3.67, 7.47) | 6.53% (4.95, 9.51) | 0.006 | 1.000 | 0.082 |
| Dmean | 17.83 Gy (14.98, 19.16) | 16.49 Gy (13.49, 17.30) | 16.60 Gy (14.98, 18.78) | 0.006 | 1.000 | 0.082 | |
| V5 | 62.46% (54.08,71.35) | 61.46% (50.92, 68.01) | 65.83% (58.94, 72.58) | 0.006 | 0.393 | 0.006 | |
| V10 | 48.48% (43.71, 53.45) | 43.76% (35.66, 49.68) | 51.87% (45.52, 56.77) | 0.006 | 0.967 | 0.006 | |
| V15 | 40.63% (37.17, 45.77) | 34.56% (28.11, 39.09) | 38.81% (34.66, 45.60) | 0.006 | 0.580 | 0.001 | |
| V20 | 35.47% (30.92, 37.54) | 28.02% (23.35, 31.08) | 30.30% (27.79, 34.55) | 0.006 | 0.006 | 0.006 | |
| V30 | 23.99% (20.37, 26.77) | 19.65% (16.30, 21.70) | 19.75% (17.69, 21.23) | 0.006 | 0.029 | 0.580 | |
| V40 | 13.26% (12.07, 18.24) | 13.61% (11.35, 15.94) | 12.63% (11.78, 14.91) | 1.000 | 1.000 | 1.000 | |
| Heart | NTCP | 27.70% (23.75, 33.50) | 27.24% (23.90, 33.10) | 27.44% (24.07, 32.40) | 1.000 | 1.000 | 1.000 |
| V45 | 6.71% (0.95, 21.71) | 4.10% (0.20, 11.15) | 4.66% (0.90, 10.06) | 0.023 | 0.023 | 1.000 | |
| V60 | 1.92% (0.04, 7.02) | 1.65% (0.00, 4.25) | 1.41% (0.05, 4.53) | 0.117 | 0.047 | 1.000 | |
| Esophagus | NTCP | 35.57% (21.88, 46.54) | 33.05% (17.92, 42.89) | 36.91% (22.89, 45.17) | 0.252 | 1.000 | 0.082 |
| V50 | 41.79% (24.36, 48.55) | 38.43% (18.63, 48.17) | 42.77% (22.23, 49.65) | 0.059 | 0.580 | 0.393 | |
| V60 | 29.55% (10.26, 38.90) | 25.28% (9.35, 39.00) | 30.25% (11.75, 39.26) | 0.146 | 1.000 | 0.018 | |
| Beam delivery time | 8.4 min (6.98, 10.18) | 10.1 min (9.05, 11.90) | 7.3 min (6.23, 8.90) | 0.252 | 0.375 | 0.006 | |
CI conformity index, HI homogeneity index, V the percentage of organ volume receiving D Gy or higher, D mean dose, D maximum dose, NTCP normal tissue complication probability, IQR interquartile range (Q1, Q3)
aThe Wilcoxon signed rank test was used by the Bonferroni correction for multiple testing
Fig. 2Isodose distribution of an example case in axial, sagittal, and coronal sections by L-IMRT, TH-IMRT and TD-IMRT. Apparent dose distribution looked better conformed to PTV in order of TH-IMRT, TD-IMRT and L-IMRT
Fig. 3Median dose-volume histograms of all ten patients for PTV, esophagus, and normal lung by L-IMRT, TH-IMRT and TD-IMRT
Comparison of correlation coefficient between parameters related with planning target volume (PTV) and lung
| Parameters | Lung | L-IMRT |
| TH-IMRT |
| TD-IMRT |
|
|---|---|---|---|---|---|---|---|
| PTV | NTCP | −0.309 | 0.385 | −0.261 | 0.467 | −0.442 | 0.200 |
| Dmean | −0.309 | 0.385 | −0.261 | 0.467 | −0.442 | 0.200 | |
| V5 | −0.273 | 0.446 | −0.321 | 0.366 | −0.406 | 0.244 | |
| V10 | −0.236 | 0.511 | −0.224 | 0.533 | −0.345 | 0.328 | |
| V15 | −0.273 | 0.446 | −0.358 | 0.310 | −0.539 | 0.108 | |
| V20 | −0.272 | 0.446 | −0.321 | 0.366 | −0.406 | 0.244 | |
| V30 | −0.236 | 0.511 | −0.224 | 0.533 | −0.345 | 0.328 | |
| V40 | −0.297 | 0.405 | −0.152 | 0.676 | −0.4303 | 0.215 | |
| PTV lengtha | NTCP | 0.663 | 0.037 | 0.802 | 0.005 | 0.632 | 0.049 |
| Dmean | 0.663 | 0.039 | 0.802 | 0.005 | 0.632 | 0.049 | |
| V5 | 0.657 | 0.039 | 0.687 | 0.028 | 0.523 | 0.121 | |
| V10 | 0.839 | 0.002 | 0.729 | 0.017 | 0.498 | 0.143 | |
| V15 | 0.851 | 0.002 | 0.802 | 0.005 | 0.644 | 0.044 | |
| V20 | 0.821 | 0.004 | 0.815 | 0.004 | 0.729 | 0.017 | |
| V30 | 0.547 | 0.102 | 0.711 | 0.021 | 0.553 | 0.097 | |
| V40 | 0.322 | 0.364 | 0.778 | 0.008 | 0.505 | 0.137 | |
| PTV ∩ Lungb | NTCP | 0.067 | 0.855 | 0.103 | 0.777 | −0.079 | 0.829 |
| Dmean | 0.067 | 0.855 | 0.103 | 0.777 | −0.079 | 0.829 | |
| V5 | 0.103 | 0.777 | 0.152 | 0.676 | 0.115 | 0.751 | |
| V10 | 0.055 | 0.881 | −0.018 | 0.960 | −0.139 | 0.701 | |
| V15 | 0.03 | 0.934 | −0.018 | 0.960 | −0.127 | 0.726 | |
| V20 | −0.055 | 0.881 | −0.042 | 0.907 | −0.103 | 0.777 | |
| V30 | −0.018 | 0.960 | 0.115 | 0.751 | −0.152 | 0.676 | |
| V40 | −0.03 | 0.934 | 0.273 | 0.446 | 0.018 | 0.960 |
PTV planning target volume, NTCP normal tissue complication probability, V the percentage of organ volume receiving D Gy or higher, Dmean mean dose
aPTV length means the superior-inferior length of the PTV
bPTV ∩ Lung means the PTV volume overlapping with the normal lung
cAll p values were calculated by the Spearman correlation test